Jim Cramer covered each holding in the Investing Club’s portfolio during the August Monthly Meeting on Thursday. He went over five stocks new investors should consider buying — and when to sell others – as the S & P 500 trades near record highs. Apple: This stock has had a big rally following the company’s announcement last week of an additional $100 billion investment in U.S. manufacturing. It just goes to show: Don’t give up on Apple. The next major test will come if a U.S. judge in Alphabet’s antitrust case ends its search exclusivity deal with the iPhone maker. If that happens, Apple management will have to come up with a plan to offset the $20 billion worth of annual payments from Alphabet. We remain confident and maintain our “hold, don’t trade” thesis on the stock. Amazon: The company’s cloud computing division, Amazon Web Services, isn’t growing as fast as hoped. That was seen in second-quarter earnings late last month. Still, we’re staying long on the stock. AWS is a huge business, and demand for cloud infrastructure is incredibly high. Abbott Laboratories: We’ve been selling down the position on the belief that Abbott just doesn’t have the same oomph that it used to. Its recent earnings report suggested the headwinds in China could be more prolonged than previously thought. Jim said if it fell much further, we’d consider rebuilding the position. Broadcom: This company is one of the linchpins of the AI trade thanks to its custom chips and networking equipment. The scale of the AI buildout is so immense that, despite all the negatives, we just have to plow through and the stay the course. We did trim our Broadcom position for a big gain on Aug. 6, to not be greedy. BlackRock: The financial stock is well positioned for more upside as the broader equities market continues to trade near record highs. That’s because BlackRock shares typically work best in a portfolio when assets are growing from appreciation and contributions. Bristol Myers Squibb: Could the rise in M & A activity and a more hands-off approach from antitrust regulators put Bristol Myers in play? Jim says it’s possible, though not certain. A forthcoming trial on its new schizophrenia drug Cobenfy could help quell some concerns about its commercial potential that arose after prior results fell short of investor expectations. Capital One: If the U.S. economy goes south, Capital One could get hit because it’s heavily levered to the health of the consumer. So far, however, there are no serious warning signs that could impact credit quality. Additionally, we continue to celebrate Capital One’s recently-completed blockbuster acquisition of Discover Financial. Costco: This is a great stock to own during macroeconomic uncertainty, as the wholesale retailer attracts value-conscious customers. “When times get tough, people go to Costco,” Jim said. Investors should consider buying more. Salesforce: The idea that “AI is eating software” has won over Wall Street, and the argument…
Read More: 5 stock buys as the S&P 500 nears record highs, plus updates on 26 more